Impact of the small molecule Met inhibitor BMS-777607 on the metastatic process in a rodent tumor model with constitutive c-Met activation

Clinical and Experimental Metastasis

Volumn 29, Issue 3, 2012, Pages 253-261

  Dai, Yao ^a   Bae, Kyungmi ^b   Pampo, Christine ^a   Siemann, Dietmar W ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

BMS 777607; c Met; KHT; Metastasis; Sarcoma

Indexed keywords

BMS 777607; PROTEIN TYROSINE KINASE INHIBITOR; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL INVASION; CELL MOTILITY; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG TARGETING; ENZYME ACTIVATION; FEMALE; GENE SILENCING; METASTASIS INHIBITION; METASTASIS POTENTIAL; MIGRATION INHIBITION; MOUSE; NONHUMAN; PROTEIN PHOSPHORYLATION; SARCOMA; SIGNAL TRANSDUCTION; TUMOR MODEL;

AMINOPYRIDINES; ANIMALS; CELL LINE, TUMOR; CELL MOVEMENT; FEMALE; HUMANS; MICE; MICE, INBRED C3H; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PROTO-ONCOGENE PROTEINS C-MET; PYRIDONES; SARCOMA, EXPERIMENTAL; SIGNAL TRANSDUCTION;

EID: 84857373138     PISSN: 02620898     EISSN: 15737276     Source Type: Journal    
DOI: 10.1007/s10585-011-9447-z     Document Type: Article

References (35)

1. C Birchmeier W Birchmeier E Gherardi, et al. 2003 Met, metastasis, motility and more Nat Rev Mol Cell Biol 4 12 915 925 14685170 10.1038/nrm1261 1:CAS:528:DC%2BD3sXpvFeju7s%3D (Pubitemid 37493640)
2. PM Comoglio S Giordano L Trusolino 2008 Drug development of MET inhibitors: targeting oncogene addiction and expedience Nat Rev Drug Discov 7 6 504 516 18511928 10.1038/nrd2530 1:CAS:528:DC%2BD1cXmsVOjsb0%3D (Pubitemid 351767118)
3. A Danilkovitch-Miagkova B Zbar 2002 Dysregulation of Met receptor tyrosine kinase activity in invasive tumors J Clin Investig 109 7 863 867 11927612 1:CAS:528:DC%2BD38Xis1Kju74%3D (Pubitemid 34275106)
4. G Maulik A Shrikhande T Kijima, et al. 2002 Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition Cytokine Growth Factor Rev 13 1 41 59 11750879 10.1016/S1359-6101(01)00029-6 1:CAS:528:DC%2BD3MXpt1ahuro%3D (Pubitemid 34436961)
5. JP Eder GF Vande Woude SA Boerner, et al. 2009 Novel therapeutic inhibitors of the c-Met signaling pathway in cancer Clin Cancer Res 15 7 2207 2214 19318488 10.1158/1078-0432.CCR-08-1306 1:CAS:528:DC%2BD1MXjvVWltrY%3D
6. WK You DM McDonald 2008 The hepatocyte growth factor/c-Met signaling pathway as a therapeutic target to inhibit angiogenesis BMB Rep 41 12 833 839 19123972 10.5483/BMBRep.2008.41.12.833 1:CAS:528:DC%2BD1MXpt1Slsg%3D%3D
7. C Boccaccio PM Comoglio 2006 Invasive growth: a MET-driven genetic programme for cancer and stem cells Nat Rev Cancer 6 8 637 645 16862193 10.1038/nrc1912 1:CAS:528:DC%2BD28XntFGlu70%3D (Pubitemid 44140861)
8. H Zhu MA Naujokas ED Fixman, et al. 1994 Tyrosine 1356 in the carboxyl-terminal tail of the HGF/SF receptor is essential for the transduction of signals for cell motility and morphogenesis J Biol Chem 269 47 29943 29948 7961992 1:CAS:528:DyaK2cXmslansLY%3D (Pubitemid 24365163)
9. SY Chen HC Chen 2006 Direct interaction of focal adhesion kinase (FAK) with Met is required for FAK to promote hepatocyte growth factor-induced cell invasion Mol Cell Biol 26 13 5155 5167 16782899 10.1128/MCB.02186-05 1:CAS:528:DC%2BD28XmsVSlu7k%3D (Pubitemid 43955827)
10. YW Zhang LM Wang R Jove, et al. 2002 Requirement of Stat3 signaling for HGF/SF-Met mediated tumorigenesis Oncogene 21 2 217 226 11803465 10.1038/sj.onc.1205004 1:CAS:528:DC%2BD38XhtVejt74%3D (Pubitemid 34102130)
11. C Migliore S Giordano 2008 Molecular cancer therapy: Can our expectation be MET? Eur J Cancer 44 5 641 651 18295476 10.1016/j.ejca.2008.01.022 1:CAS:528:DC%2BD1cXjtlWju70%3D
12. CM Stellrecht V Gandhi 2009 MET receptor tyrosine kinase as a therapeutic anticancer target Cancer Lett 280 1 1 14 19100682 10.1016/j.canlet.2008.10.045 1:CAS:528:DC%2BD1MXlvF2kt7k%3D
13. J Goldberg GD Demetri E Choy, et al. 2009 Preliminary results from a phase II study of ARQ 197 in patients with microphthalmia transcription factor family (MiT)-associated tumors J Clin Oncol 27 15s 10502
14. RW Ross M Stein J Sarantopoulos, et al. 2007 A phase II study of the c-Met RTK inhibitor XL880 in patients (pts) with papillary renal-cell carcinoma (PRC) J Clin Oncol 25 18s 15601
15. Schiller JH, Akerley WL, Brugger W, et al. (2010) Results from ARQ 197-209: a global randomized placebo-controlled phase II clinical trial of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated EGFR inhibitor-naive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 28(18s):(suppl; abstr LBA7502)
16. GM Schroeder Y An ZW Cai, et al. 2009 Discovery of N-(4-(2-amino-3- chloropyridine-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1, 2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamily J Med Chem 52 5 1251 1254 19260711 10.1021/jm801586s 1:CAS:528:DC%2BD1MXhvVCnsLc%3D
17. JG Christensen R Schreck J Burrows, et al. 2003 A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo Cancer Res 63 21 7345 7355 14612533 1:CAS:528:DC%2BD3sXovVGltL4%3D (Pubitemid 37413476)
18. SG Buchanan J Hendle PS Lee, et al. 2009 SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo Mol Cancer Ther 8 12 3181 3190 19934279 10.1158/1535-7163.MCT-09-0477 1:CAS:528:DC%2BD1MXhsFCitbzI
19. Y Dai DW Siemann 2010 BMS-777607, a small-molecule met kinase inhibitor, suppresses hepatocyte growth factor-stimulated prostate cancer metastatic phenotype in vitro Mol Cancer Ther 9 6 1554 1561 20515943 10.1158/1535-7163.MCT- 10-0359 1:CAS:528:DC%2BC3cXntFGgsLs%3D
20. M Dong L Rice S Lepler, et al. 2010 Impact of the Src inhibitor saracatinib on the metastatic phenotype of a fibrosarcoma (KHT) tumor model Anticancer Res 30 4405 4414 21115886 1:CAS:528:DC%2BC3MXhs1ajsw%3D%3D
21. DW Siemann 1995 Chemosensitization of CCNU in KHT murine tumor cells in vivo and in vitro by the agent RB 6145 and its isomer PD 144872 Radiother Oncol 34 1 47 53 7792398 10.1016/0167-8140(94)01498-R 1:CAS:528:DyaK2MXltFeqt7k%3D
22. L Rice C Pampo S Lepler, et al. 2011 Support of a free radical mechanism for enhanced antitumor efficacy of the microtubule disruptor OXi4503 Microvasc Res 81 44 51 20974154 10.1016/j.mvr.2010.10.003 1:CAS:528:DC%2BC3MXjsVOktg%3D%3D
23. EM Rosen SK Nigam ID Goldberg 1994 Scatter factor and the c-met receptor: a paradigm for mesenchymal/epithelial interaction J Cell Biol 127 6 Pt 2 1783 1787 7806559 10.1083/jcb.127.6.1783 1:CAS:528:DyaK2MXivFejtrY%3D
24. S Benvenuti PM Comoglio 2007 The MET receptor tyrosine kinase in invasion and metastasis J Cell Physiol 213 2 316 325 17607709 10.1002/jcp.21183 1:CAS:528:DC%2BD2sXhtFKnu7rM (Pubitemid 47509708)
25. JH Lee SU Han H Cho, et al. 2000 A novel germ line juxtamembrane Met mutation in human gastric cancer Oncogene 19 43 4947 4953 11042681 10.1038/sj.onc.1203874 1:CAS:528:DC%2BD3cXnslGqsbo%3D
26. PC Ma MS Tretiakova AC MacKinnon, et al. 2008 Expression and mutational analysis of MET in human solid cancers Genes Chromosomes Cancer 47 12 1025 1037 18709663 10.1002/gcc.20604 1:CAS:528:DC%2BD1cXhtlWns7vE
27. B Lal S Xia R Abounader, et al. 2005 Targeting the c-Met pathway potentiates glioblastoma responses to gamma-radiation Clin Cancer Res 11 12 4479 4486 15958633 10.1158/1078-0432.CCR-05-0166 1:CAS:528:DC%2BD2MXltFeks7w%3D (Pubitemid 40825638)
28. MV Karamouzis PA Konstantinopoulos AG Papavassiliou 2009 Targeting MET as a strategy to overcome crosstalk-related resistance to EGFR inhibitors Lancet Oncol 10 7 709 717 19573800 10.1016/S1470-2045(09)70137-8 1:CAS:528: DC%2BD1MXotFynsbs%3D
29. PC Ma MS Tretiakova V Nallasura, et al. 2007 Downstream signalling and specific inhibition of c-MET/HGF pathway in small cell lung cancer: implications for tumour invasion Br J Cancer 97 3 368 377 17667909 10.1038/sj.bjc.6603884 1:CAS:528:DC%2BD2sXotlSgt74%3D (Pubitemid 47196754)
30. Z Tang R Du S Jiang, et al. 2008 Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer Br J Cancer 99 6 911 922 19238632 10.1038/sj.bjc.6604559 1:CAS:528:DC%2BD1cXhtV2jurrI
31. AT Liao J McCleese S Kamerling, et al. 2007 A novel small molecule Met inhibitor, PF2362376, exhibits biological activity against osteosarcoma Vet Comp Oncol 5 3 177 196 19754789 10.1111/j.1476-5829.2007.00137.x 1:CAS:528:DC%2BD2sXhtV2ns7jF
32. M Zillhardt JG Christensen E Lengyel 2010 An orally available small-molecule inhibitor of c-Met, PF-2341066, reduces tumor burden and metastasis in a preclinical model of ovarian cancer metastasis Neoplasia 12 1 1 10 20072648 1:CAS:528:DC%2BC3cXmtlGiug%3D%3D
33. G Cassinelli C Lanzi G Petrangolini, et al. 2006 Inhibition of c-Met and prevention of spontaneous metastatic spreading by the 2-indolinone RPI-1 Mol Cancer Ther 5 9 2388 2397 16985073 10.1158/1535-7163.MCT-06-0245 1:CAS:528:DC%2BD28Xps1ynsbs%3D (Pubitemid 44530476)
34. N Munshi S Jeay Y Li, et al. 2010 ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity Mol Cancer Ther 9 6 1544 1553 20484018 10.1158/1535-7163.MCT-09-1173 1:CAS:528:DC%2BC3cXntFGgsL0%3D
35. M Stoker E Gherardi M Perryman, et al. 1987 Scatter factor is a fibroblast-derived modulator of epithelial cell mobility Nature 327 6119 239 242 2952888 10.1038/327239a0 1:STN:280:DyaL2s3gtF2ltA%3D%3D (Pubitemid 17071053)